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CD57+ T-cells are a subpopulation 
of T-follicular helper cells in nodular lymphocyte 
predominant Hodgkin lymphoma
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Abstract 
Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is characterized by lymphocyte-pre-
dominant (LP) cells in a background of CD4+ CD57+ T-cells. These cells are normally present in the germinal center 
of lymphoid tissues. The cells rosetting LP cells are described to be PD-1 and BCL-6 positive, which are markers of 
T-follicular helper cells. This study was designed to address the question: are the CD57+ T cells in germinal centers of 
tonsil and NLPHL TFH cells?
Results: Immunohistochemistry was performed on tonsil and NLPHL. For tonsil, cells per germinal center and for 
NLPHL, the area around LP cells was counted. Cells rosetting LP cells were also determined. In addition, flowcytom-
etry was performed on cell suspensions. Cells directly rosetting LP cells are positive for CD57 and/or for two markers 
of T-follicular helper (TFH) cells, PD-1 and BCL-6. We show that in both tonsil and NLPHL more than 90 % of CD57+ 
T-cells are also positive for PD-1, whereas roughly half of the PD-1+ T-cells are CD57+. CD57+ cells co-express BCL-6 
in tonsil and in the rosetting cells of NLPHL.
Conclusions: We conclude that CD57+ T-cells are TFH cells and form a subpopulation of TFH cells in tonsils and 
NLPHL.
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Background
Nodular lymphocyte predominant Hodgkin lymphoma 
(NLPHL) accounts for 5  % of all Hodgkin lymphoma 
cases. Lymphocyte-predominant (LP) cells, the neoplas-
tic cells of NLPHL, compose only 1  % of the total cell 
population and reside in a background of lymphoid cells. 
One of the prominent cell types in NLPHL are the CD4+ 
CD57+ T-cells. These CD57+ T-cells are normally pre-
sent in the germinal centers of tonsil and form about 
5–8 % of all cells. In NLPHL, CD4+ CD57+ T-cells form 
20–40 % of the total cell population and they are present 
mostly around the LP cells [1]. Another CD4+ T-cell 
subpopulation in the germinal centers of tonsils are the 
T-follicular helper (TFH) cells. TFH cells are critical 
cells for B-cell maturation [2]. They can be distinguished 
from other T helper subpopulations by co-expression 
of the TFH cell associated transcription factors c-Maf 
and BCL-6 in addition to expression of PD-1, CXCR5, 
CXCL13 and ICOS [3]. In NLPHL, BCL-6+ CD57+ 
T-cells [4] and c-Maf+ CD57+ T-cells [5] rosetting the 
LP cells have been reported. Expression of known TFH 
cells markers such as PD-1 has also been observed on 
rosetting cells in NLPHL and PD-1 outperforms CD57 as 
an additional diagnostic tool in the diagnosis of NLPHL 
[6, 7]. This study was designed to determine whether 
CD57+ T-cells in NLPHL are TFH cells and if they are 
similar to the TFH cells in normal tonsil tissue.
Materials and methods
Paraffin blocks of 6 tonsils (chronic tonsillitis in young 
patients) and lymph nodes of 8 NLPHL patients were 
used for staining. For flowcytometry, cell suspensions 
stored in liquid nitrogen of 7 tonsils and the same 8 
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NLPHL lymph nodes were used. The study protocol was 
consistent with international ethical and professional 
guidelines (the Declaration of Helsinki and the Inter-
national Conference on Harmonization Guidelines for 
Good Clinical Practice).
For immunohistochemistry and immunofluorescence 
stainings of PD-1 (1:100, Acris, Herford, Germany) in 
combination with CD57 (1:50, Monosan, Uden, The 
Netherlands) antigen retrieval was performed with 0.1 M 
TRIS/HCl pH9 in a microwave. For BCL-6 (1:20, BD bio-
sciences, San José, CA, USA) in combination with CD57 
and CD20 (1:200, Dako, Glostrup, Denmark) antigen 
retrieval in a high pressure cooker in 1 mM EDTA pH8 
was performed. In order to count the CD57+ and PD-1+ 
cells in tonsils, all PD-1+, CD57+ and double positive 
cells in at least five germinal centers were counted in each 
sample. In NLPHL, cells present around LP cells in 10 
areas with the magnification of 200× were counted for 
CD57+, PD-1+ and double positive cells. In addition, in 
each case the rosetting cells of at least 15 LP cells were 
counted with the magnification of 400×. Standard labo-
ratory procedures were followed for all stainings, includ-
ing appropriate positive and negative controls.
For flowcytometry 0.5 × 106 cells were incubated with 
anti-CD4, anti-PD-1, and anti-CD57 (BD biosciences). 
Cells were acquired on a Calibur (BD biosciences) and 
analyzed with Winlist software.
A Mann–Whitney test was applied to determine sig-
nificant differences between groups.
Results
Immunohistochemistry and immunofluorescence results
Immunofluorescence staining of PD-1 in combination 
with CD57 showed that almost all CD57+ cells in the 
germinal centers were also PD-1 positive, while part 
of the PD-1+ cells were negative for CD57 (Fig.  1a, b). 
Counting of all available (5–10) germinal centers in each 
tonsil and 10 LP cell rich areas in NLPHL for PD-1 and 
CD57 positivity indicated that 94 and 92 % of the CD57+ 
T-cells expressed PD-1 in both tonsil and NLPHL 
(Fig. 1c). Of the PD-1+ T-cells, 48 and 39 % were CD57+ 
in tonsil and NLPHL, respectively (Fig. 1d, e).
We next counted the cells immediately rosetting LP 
cells for PD-1 and CD57 expression (17–45 LP cells per 
case). We observed two populations of cells, single PD-1 
expressing cells and cells expressing both PD-1 and CD57 
(Fig. 1f ). Virtually all rosetting cells were PD-1 positive, 
while the percentage of PD-1+ CD57+ varied between 0 
and 58 % (Fig. 1g).
Immunohistochemical staining for BCL-6, CD57 and 
CD20 indicated that almost all CD57+ T-cells in the 
germinal center of tonsils were BCL-6 positive (Fig. 1h). 
In addition, we observed multiple BCL-6 single positive 
T-cells. In NLPHL we saw a similar pattern, with all 
CD57+ T-cells within the area around the LP cells as well 
as the LP rosetting cells being BCL-6 positive (Fig. 1i). In 
addition, we also observed a substantial number of sin-
gle BCL-6+ T-cells in the areas of the LP cells as well as 
directly rosetting around the LP cells.
Flowcytometry results
In both tonsil and NLPHL suspensions we gated on the 
CD4+ T-cells and we determined the percentages of 
PD-1 and CD57 positive cells in the whole cell suspen-
sion. The percentage of CD57+ cells was 5 % on average 
in tonsil, and 25  % on average in NLPHL, and was the 
only significant difference (p =  .042) (Fig. 2a). A higher 
percentage of PD-1+ cells was observed in NLPHL com-
pared to tonsil, 60 vs 33 % (Fig. 2b). Almost all CD57+ 
T-cells were positive for PD-1, i.e. 96 % in tonsil and 94 % 
in NLPHL (Fig. 2c). In contrast, only part of the PD-1+ 
T-cells were positive for CD57, i.e. 17  % in tonsil and 
38 % in NLPHL.
Discussion
To establish whether CD57+ T-cells in NLPHL are TFH 
cells, we analyzed co-expression with PD-1 and BCL-6. 
We showed that more than 90 % of CD57+ cells in the 
germinal center of tonsil and the tumor areas in NLPHL 
are PD-1 positive. These CD57+ cells are a subpopulation 
of the PD-1+ population as they represent an average 
of 48 % of the PD-1+ cells in germinal centers in tonsil 
and 39 % in the tumor areas in NLPHL. There is a large 
variation in the percentages of CD57+ cells in the PD-1 
subpopulation in NLPHL, this could be due to the differ-
ences in morphological patterns of the cases. It has been 
described that in diffuse areas of the tumor less PD-1 and 
CD57 positivity is seen [7]. Of the 8 cases tested 6 (cases 
1–6) were classic nodular, case 7 was a case with T-cell 
rich nodules and case 8 was a case with prominent extra 
nodular LP cells that was CD57 negative. The large vari-
ation in percentage within the individual cases cannot 
be found in differences in diffuse and nodular areas. The 
lymphocytes rosetting the LP cells are PD-1 positive as 
reported earlier [6] and CD57+ cells form a subpopula-
tion of the rosetting cells in most patients. Flowcytom-
etry confirmed that in both tonsil and NLPHL more 
than 90  % of CD57+ T-cells express PD-1. In NLPHL, 
the percentage of CD57+ cells in the PD-1 population is 
comparable with staining results (39 and 38  %). In ton-
sil, the percentage of CD57+ cells in the PD-1 popula-
tion is much lower as determined by flowcytometry (48 
vs 17 %). The explanation for this discrepancy might be 
that PD-1+ T-cells are also present outside the germinal 
centers in tonsil [8], while CD57+ T-cells are only found 
in the germinal centers [9]. For the immunostaining 
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we specifically counted the germinal centers in tonsils, 
which has resulted in higher percentages.
CD57+ cells in tonsil as well as in the areas around 
the tumor cells and the LP rosetting cells express BCL-6 
in concurrence with previous studies about the pres-
ence of BCL-6+ LP rosetting T-cells [4, 10]. A signifi-
cant increase was observed by flowcytometry in terms of 
CD57 percentages in NLPHL cases compared to tonsil, 
which has been reported previously in flowcytometry [1]. 
Co-expression of PD-1 as a known marker of TFH cells 
with the TFH cell associated transcription factor BCL-6 
suggests that these CD57+ T-cells most likely are TFH 
cells. This is also supported by the common expression of 
c-Maf, which is another transcription factor of TFH cells, 
in LP rosetting cells [5].
Although TFH cells are important in providing help 
to B-cells especially in the area of antibody responses 
[2], CD57+ CD4 cells have been described as cells that 
are not able to proliferate due to chronic antigen expo-
sure [11]. These cells produce interferon-γ but are not 
able to produce interleukin-2 [10, 12] and have the abil-
ity to suppress activation of conventional CD4 cells 
[12]. Their function in NLPHL is not clear, but CD57+ 
TFH cells could play a role in immune suppression of 
the microenvironment. The presence of PD-1+ cells has 
recently gained interest as a potential therapeutic target 
Fig. 1 Immunohistochemistry results of tonsil and NLPHL. a PD-1 (red) and b CD57 (green) fluorescent staining of tonsil. Shown is exactly the same 
area of a germinal center (×400) with different filters. Arrows indicate some of the PD-1+ cells which are CD57−. c Percentage of PD-1+ cells in 
the CD57+ T-cell population in tonsil and NLPHL; 94 and 92 % of the CD57+ cells express PD-1 in tonsil and NLPHL, respectively. d Percentage of 
CD57+ cells in the PD-1+ population in tonsil; an average of 48 % of PD-1+ cells are CD57+. e Percentage of CD57+ cells in PD-1+ population in 
NLPHL, an average of 39 % of PD-1+ cells are CD57+. f PD-1(red) and CD57 (green) staining of NLPHL (×800). The nucleus is counter stained with 
DAPI (blue). In the center an LP cell surrounded by PD-1+ cells, three of which are also positive for CD57 (green yellow) is shown. g Percentage of 
CD57+ cells in PD-1+ rosetting cells in NLPHL, the range of PD-1+ LP rosetting cells that are CD57+ varies from 0 to 58 %. h CD57 (dark red rim), 
BCL-6 (brown nucleus), CD20 (blue) staining in tonsil (×400). CD57+ cells are also BCL-6+. Some of the CD20+ cells also express BCL-6. Part of the 
cells are single positive for BCL-6. i CD57 (dark red rim), BCL-6 (brown nucleus), CD20 (blue) staining in NLPHL: (×600). An LP cell (CD20+ and BCL-
6+) is surrounded with two types of cells: BCL-6 and CD57 double positive cells and BCL-6 single positive cells
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in cancer. In classical Hodgkin lymphoma blocking of 
PD-1 by nivolumab was very successful [13]. The pres-
ence of PD-1+ T cells seems less predictive of the success 
of blocking PD-1/PD-L1 however as the expression of 
PD-L1 by tumor cells, and PD-L1 expression in NLPHL is 
found in few cases [14].
In conclusion, we show that LP cells are rosetted by 
PD-1+ BCL-6+ double and PD-1+ CD57+ BCL-6+ tri-
ple positive T-cells. In addition, we show a remarkable 
increase in the population of CD4+ PD-1+ and CD4+ 
PD-1+ CD57+ T-cells in NLPHL. CD57 positive CD4 
cells are a subpopulation of TFH cells with a potential 
role in the pathogenesis of NLPHL.
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